Join
Live feed
·
PRReleasevia Quantisnow
Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

ByQuantisnow·Wall Street's wire, on your screen.
FUSN· Fusion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FUSN (Fusion Pharmaceuticals Inc.) and more on Quantisnow.